U.S. Capital Wealth Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-23,427	Closed	-$553K	–	1002
2025 Q3	$553K	Sell	23,427 -6,287	-21%	-$139K	0.01%	612
2025 Q2	$609K	Buy	29,714 +4,552	+18%	+$91.7K	0.02%	548
2025 Q1	$516K	Buy	25,162 +6,053	+32%	+$135K	0.02%	581
2024 Q4	$432K	Buy	+19,109	New	+$459K	0.01%	598

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

U.S. Capital Wealth Advisors's IDNA Position: Q4 2025 in Review

U.S. Capital Wealth Advisors sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q4 2025, closing a stake of 23,427 shares — an estimated $553K sold.

U.S. Capital Wealth Advisors first reported a position in IDNA in Q4 2024 and held it in 4 quarters. The position peaked at $609K in Q2 2025. 58 funds tracked by Wall St. Rank hold IDNA as of Q4 2025.

U.S. Capital Wealth Advisors reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q4 2025 after selling out during the quarter.
U.S. Capital Wealth Advisors sold 23,427 iShares Genomics Immunology and Healthcare ETF shares in Q4 2025, an estimated $553K.
U.S. Capital Wealth Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2024 and held it in 4 quarters.
U.S. Capital Wealth Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $609K in Q2 2025.
58 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q4 2025.

Based on U.S. Capital Wealth Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.